Listed

PharmaCyte Biotech, Inc.: Form 10-K for the period ended Apr 30, 2012

Filed with the SEC on Aug 14, 2012 and accepted by EDGAR at Aug 14, 2012, 15:48 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-04-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2011-05-01 to 2012-04-30$66.6kus-gaap:Revenues
Cost of revenue12 months2011-05-01 to 2012-04-30$19.4kus-gaap:CostOfRevenue
Gross profit12 months2011-05-01 to 2012-04-30$47.2kus-gaap:GrossProfit
Interest expense12 months2011-05-01 to 2012-04-30$241.2kus-gaap:InterestExpense
Net income12 months2011-05-01 to 2012-04-30−$1.9mus-gaap:NetIncomeLoss
Basic EPS12 months2011-05-01 to 2012-04-30$0.01us-gaap:EarningsPerShareBasic
Operating cash flow12 months2011-05-01 to 2012-04-30−$259.3kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2012-04-30$15.7kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-04-30$1.1mus-gaap:AssetsCurrent
Total assetsAt period end2012-04-30$2.1mus-gaap:Assets
Current liabilitiesAt period end2012-04-30$3.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2012-04-30$3.8mus-gaap:Liabilities
Shareholders' equityAt period end2012-04-30−$2.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001262463-12-000335. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.